Category: Health

  • Meezan Bank and Roche Pakistan Join Forces to Combat Breast Cancer

    Meezan Bank, Pakistan’s first and largest Islamic Bank, has joined hands with Roche Pakistan, one of the world’s leading biotech companies, in an initiative aimed at alleviating the financial burden of breast cancer treatment for patients across Pakistan.

    Breast cancer remains a critical health challenge in Pakistan, claiming numerous lives and impacting countless families each year. Recognizing the urgency of addressing this pressing issue, Meezan Bank has pledged its unwavering support to ease the financial strain associated with diagnosis, medication, and therapy for affected individuals and their families.

    The primary aim of this sponsorship is to offer the finest medical services to breast cancer patients. Additionally, it endeavors to educate individuals on navigating financial obstacles and accessing treatment seamlessly, ensuring a hassle-free experience.

    Acknowledging the urgent need for intervention, Meezan Bank has taken action to extend a helping hand. Through collaboration with Roche Pakistan, the Bank is enabling access to essential breast cancer treatment, ensuring that financial constraints do not hinder patients from receiving crucial care.

    Also Read: IPAK Raises PKR 1.77 billion in Book Building Process!

  • Rare Diseases Need Government Attention

    In recognition of Rare Disease Day, Roche Pakistan Limited held a panel discussion and press briefing to raise awareness about rare diseases in Pakistan and to emphasize the unmet needs of patients especially when it comes to awareness, funding, and government support. The panel comprised MD Roche Pakistan, Ms. Hafsa Shamsie, Roche’s Head of Medical, Dr. Yasir Adnan as well as paeds neurologist Dr. Raman Kumar and hematologist Dr. Munira Borhany and Dr. Saqib, Director Health, Services, Health Department, Govt. of Sindh.

    Ms. Hafsa Shamsie, MD Roche highlighted the fact that even for those who have been diagnosed, the lack of government healthcare spending and support makes the treatment burden for rare diseases even more difficult to bear. Rare disease sufferers are the neglected outliers in Pakistan’s healthcare system. Roche is a company that is committed to serving rare disease patients by bringing innovative treatments that can help patients live a fully normal life or at least a much better quality of life. But, treatment is one side of the picture. Ensuring that patients have awareness about rare diseases, and access to these standard-of-care treatments is the other side of the picture. She shared that since 2017, Roche has run a Patient Support Program that has helped almost 25,000 patients with free-of-cost treatment for several diseases including Spinal Muscular Atrophy and Multiple Sclerosis. But as the burden of disease grows no one company or entity can go it alone. That is why it is critical to have the government on board through public-private partnerships. This will help to support rare disease patients by including funding for standard-of-care treatments in government healthcare programs. She said rare disease patients deserve the same care, attention, and inclusion as other patients and that is why it is time that “Recognizing Rare” becomes a healthcare priority too.

    Dr. Yasir Adnan explained that worldwide about 300 million people live with a rare disease. Moreover, with Pakistan having over 240 million people, the rare disease incidence in this country becomes more acute with such a large population. Rare diseases like Multiple Sclerosis, Spinal Muscular Atrophy, and Hemophilia pose not only debilitating physical and health challenges for the sufferer but also grave challenges for the families of sufferers and the society at large. Without treatment, children are deprived of the chance for a normal life such as in the case of hemophilia, young women lose out on their most productive years as in the case of multiple sclerosis, and even SMA patients who could perhaps regain function are unable to do so. One of the other problems is that rare diseases can sometimes be invisible to others and it can take years sometimes for someone to even get a diagnosis. Worse still, these people are often lost within a healthcare system that fails to give them answers.

    He stated that worldwide, less than 10% of patients with rare diseases are treated. So the number of rare disease sufferers coming through the system is already an underrepresentation – especially in a country with poverty and low literacy. He talked about Multiple sclerosis (MS) – a condition that can affect the brain and spinal cord, causing a wide range of potential symptoms, including problems with vision, arm or leg movement, sensation, or balance. It’s a lifelong condition that can sometimes cause serious disability. It’s most commonly diagnosed in people in their 20s, 30s, and 40s although it can develop at any age. It’s about 2 to 3 times more common in women than men. MS is a disabling and stigmatizing disease that can lead to social isolation and exclusion. Governments, national healthcare systems, employers, and legislation must enable people with MS to achieve a quality of life. This includes diagnosing and treating the disease early to stave off relapses and prevent the progression of disability, alongside protective legislation to enable people to access affordable treatment as well as remain in employment.

    Dr. Raman Kumar said spinal muscular atrophy (SMA) is a severe neuromuscular disease and one of the leading genetic causes of infant death.  He said that even though there was a lack of data to assess the prevalence of SMA in Pakistan, cousin marriages are the most common reason attributed for its occurrence and Pakistan had a very high frequency of cousin marriages. Dr. Kumar suggested that Govt/the policymakers should work on establishing National/Provincial Policies for Rare Diseases and capacity building of healthcare infrastructure to serve rare disease patients. Further, he encouraged all relevant stakeholders to empower people living with SMA for equitable access to diagnosis, treatment care, and social opportunities.

    Dr. Munira Borhany explained that Hemophilia A is a debilitating and life-threatening bleeding disorder. Hemophilia A severely affects the quality of life of patients who may experience spontaneous bleeding and bleeding due to trauma within the muscles, joints, and other internal organs, often 15-20 times a year. These bleeding episodes may either end up being fatal or result in permanent joint disability. Hemophilia A, patients experience long-term psychosocial impacts as well. Children face barriers to socialization (missed school, unable to play with friends), leading to an impact on education and career decisions. Later in life, they face workplace issues (missed days at work), and have to constantly rely on carers to manage bleeds. She emphasized that in Pakistan there was a severe lack of hemophilia management infrastructure and was not generally treated in tertiary care hospitals. In addition, hemophilia standard-of-care treatment was generally not covered under any government health program. As a result, patients were forced to use conventional treatments, which hindered their chances to live normal lives. She said there is a dire need for our provincial governments to provide the utmost support, especially in terms of standard-of-care treatment, so that patients could live normal lives and become active members of society.

    Also Read: 35th ‘Vision Eye Camp’ held to Bring Sight and Hope to almost 600 patients in Lahore and Karachi

  • Aga Khan University Receives $1.5 Million Boost to Revolutionize Treatment of β-Thalassemia and Sickle Cell Disease

    Aga Khan University has received a $1.5 million grant from Wellcome Leap, a leading global health innovation organization. This significant grant will support a project that seeks to transform the treatment of β-Thalassemia and Sickle Cell Disease (SCD), which have plagued South Asia, particularly Pakistan. These diseases have not only caused significant suffering but also imposed a heavy economic burden on society. This competitive grant provides a significant boost to the development of innovative gene therapies.

    Both β-Thalassemia and SCD are hereditary conditions, arising from genetic anomalies affecting the production of hemoglobin, a vital protein responsible for transporting oxygen in our bloodstream. In Pakistan, where many marriages occur within families (such as cousins), more than 70% of marriages involve relatives. This increases the chances of inheriting these genetic errors. In Pakistan, more than 7% of the population carries the β-Thalassemia gene, while the prevalence of SCD is estimated to be 2%. Due to these high carrier rates, Pakistan has a large population of over 100,000 registered Thalassemia patients with approximately 9,000 children born with the severe form known as Thalassemia Major. Treatment of these patients is significantly costly, requiring frequent blood transfusions and iron chelation therapy. Sadly, the current treatment options are challenging to sustain, with less than one percent of patients surviving beyond the age of 20.

    Thalassemia varies worldwide, with over 300 different mutations in various regions, including Pakistan. Due to this diversity and the increasing focus on personalized treatments or therapies developed in one country may not effectively address the unique challenges faced by patients in another. Thus, localized research is crucial to comprehend region-specific mutations and develop tailored solutions.

    Dr Afsar Mian, Assistant Professor at Aga Khan University, and the principal investigator of the project, explains the limitations of the only known curative therapy, allogenic hematopoietic stem cell (HSC) transplantation, which is dependent on donor compatibility, expensive and can result in treatment failure. Dr Mian states, “This limits access to treatment and highlights the need for alternative therapies.”

    In recent years, the introduction of transplantation of genetically modified stem cells offers hope for treating β-Thalassemia and SCD. Recent advancements in gene editing technologies such as CRISPR-Cas9, offer hope to correct genetic mutations. This involves editing stem cells taken from patients using CRISPR-Cas9 before transplanting into the same patient. The research team at AKU aims to explore two advanced gene editing techniques: base editing and prime editing. These techniques have gained popularity due to their precision, specificity, and minimal unintended side effects compared to CRISPR-Cas9 technology.

    “CRISPR is a remarkable technology that allows scientists to make changes in our DNA. However, prime editing takes gene editing to the next level,” says Dr Mian. “It offers even more precision and versatility in fixing genetic errors, reduces the chances of unintended effects, and increases the effectiveness of the editing process.”

    The initial testing phase of this new gene editing therapy will take place in the laboratory, where stem cells with the remarkable ability to develop into any cell type will be collected from Thalassemia and SCD patients. If laboratory tests prove successful, the next step will involve pre-clinical trials on animals. These trials will aim to assess the safety of the proposed treatments before they can be tested on patients. This careful progression from laboratory testing to pre-clinical trials ensures that the potential therapies are thoroughly examined and meet the necessary safety standards before further advancement.

    The study team at AKU includes Dr. Afsar Mian, Dr. Salman Kirmani, Dr Ambreen Fatima, Dr Fawad Ur Rehman, and Dr Irfan Hussain.

    This groundbreaking approach offers newfound hope and relief to a significant number of Thalassemia patients, paving the way for targeted and efficient solutions customized to the distinct genetic profiles of affected individuals.

    Also Read: Non-Stop Evening OPD Introduced at Mayo Hospital, Lahore

  • 35th ‘Vision Eye Camp’ held to Bring Sight and Hope to almost 600 patients in Lahore and Karachi

    Vision Eye Care, an international relief organization dedicated to the prevention of blindness with a footprint in 39 countries around the world, launched its 35th cataract surgery project, the ‘Vision Eye Camp,’ in Karachi and Lahore. Organized through sponsorships from the Parwaaz Financial Services Limited, CITI Group, Hanananum Foundation, Lotte Akhtar Beverages (Pvt) Ltd, Haimont Group, and Galleria Design, the Camp aimed to treat 600 patients and perform 150 cataract surgeries.

    The Camp was organized with three distinguished ophthalmologists, Dr. Donghae Kim, Dr. Dongkwon Lim, and Dr. Mathew Akashi (Medical Director, UCH Lahore), along with four nurses and five volunteers, offering high-quality eye health services. Having embarked on blindness prevention projects in Pakistan since 2002, Vision Care has played a key role in facilitating patients facing vision impairments. In Lahore, the organization initiated public eye health services in 2006. By offering opportunities for sight restoration, Vision Care endeavors to not only conduct cataract surgeries for low-income groups but also implement eye screening programs and provide magnifiers to those who lack access to adequate medical care. Biannually, Vision Care holds the ‘Vision Eye Camp’ in Pakistan, conducting over 100 cataract surgeries each session.

    Mr. Kim Kooboong, Chairman of the Korean Society in Pakistan, lauded the volunteer activities of Koreans, including the Vision Eye Camp, emphasizing their significant contribution to the friendship between both nations. He highlighted the added significance this year, as Pakistani companies actively participated in sponsoring the event.

    Since its inception in 2002, Vision Eye Care has treated 24,429 patients and performed 3,277 cataract surgeries across seven regions, including Karachi and Lahore.

    About Vision Eye Care:

    Vision Eye Care is an international relief organization dedicated to the prevention of blindness, currently working in 39 countries around the world. To date, they have treated over 170,000+ patients and performed 27,000+ sight-restoring surgeries to share the joy of sight-restoring. Vision Care helps those who would not otherwise have access to quality eye care, by providing cataract surgery and other medical services to improve and transform lives. They aim to improve the lives of all people throughout the world who are suffering from vision problems, regardless of their race, color, creed, national origin, or religion.

    Also Read: Bridging the Evidence Gap for Children and Adolescents

  • Non-Stop Evening OPD Introduced at Mayo Hospital, Lahore

    The Government of Punjab has introduced extended evening OPD timings for pediatrics till 8 pm daily at Mayo Hospital, Lahore. This initiative has been implemented in collaboration with ChildLife Foundation to facilitate the increased flow of children coming in for treatment and seeks to address the consultation needs of sick children, particularly during the evening hours when patient flow typically surges in the Emergency Room (ER).

    The extended evening OPD, operational from 02:00 pm to 08:00 pm, aims to effectively manage the patient flow coming to the hospital’s children’s emergency. The govt doctors and clinical team of ChildLife Foundation are working together to provide consultations to children in need, with an average of 100 patients being attended to daily. Moreover, Mayo Hospital provides prescribed medicines free of cost to children from the outdoor pharmacy, ensuring that financial constraints do not hinder access to emergency care.

    This collaborative effort represents a shared vision of ensuring the well-being of children and reflects the impact of public-private partnerships towards addressing healthcare challenges and making Pakistan a child-safe country. The initiative is a significant step towards ensuring that no child in Lahore is deprived of timely and quality medical attention free of cost.

    Also Read: Shell Pakistan and LRBT Collaborate for Free Eye Camps for Mechanics

  • Shell Pakistan and LRBT Collaborate for Free Eye Camps for Mechanics

    Shell Pakistan Limited (SPL) organized an eye camp for mechanics in partnership with Layton Rahmatulla Benevolent Trust (LRBT). The mechanics were provided free eye screening to ensure healthy eyesight.

    As part of its community outreach program, SPL, in collaboration with LRBT, has been providing eye testing to community members.

    The Chief Executive and Managing Director of Shell Pakistan Limited, Waqar Siddiqui, stated: “We aim to be a good neighbour wherever we work, by contributing to the well-being of our communities. Shell’s social performance programmes enable us to share with communities the benefits that economic development brings while creating a sustainable business environment.”

    A team of ophthalmologists and support staff from LRBT conducts these eye tests and dispenses medicine for eye ailments. If further treatment is required, patients are referred to the nearest LRBT hospital, receiving additional free treatment.

    Shell invests in the communities where we live and operate. Investment in local communities is tailored to the community’s needs and aligned with Shell’s business objectives.

    Also Read: SIEHS, CHILDLIFE sign MoU to enhance pediatric emergency, health services across Sindh

  • Bridging the Evidence Gap for Children and Adolescents

    In a groundbreaking article published in the prestigious Nature Medicine journal, experts from various parts of the world collaborated to address evidence gaps for non-communicable diseases (NCDs) in children and adolescents. Notable experts, including Dr Zulfiqar Bhutta and Dr Jai Das from the Institute for Global Health and Development at Aga Khan University (IGHD-AKU) in Pakistan, partnered with Dr Rehana Salam from the University of Sydney in Australia, Laura Lewis-Watts from the Hospital for Sick Children (SickKids) in Canada, Maryam Hameed Khan, currently pursuing her Master of Public Health at Johns Hopkins University in the United States, and Syed Saqlain Ali Meerza from IGHD-AKU. Dr. Rehana Salam played a lead role in the study, conducting the research, while Dr. Bhutta conceptualized, and designed the study, and secured financing.

    The research, titled “An evidence gap map of interventions for noncommunicable diseases and risk factors among children and adolescents,” sheds light on the significant burden these diseases place on young lives and carry on in adulthood. These diseases include obesity, mental health conditions, type 1 diabetes, cancers, cardiovascular and chronic respiratory diseases, and substance misuse, which collectively contribute to 41% of disability-adjusted life years related to NCDs among children and adolescents worldwide. Dr Rehana Salam adds, “Our research underscores the imperative of addressing the evidence gaps for non-communicable diseases in children and adolescents. By focusing on LMICs and collaborating across borders, we aim to pave the way for impactful interventions that can shape the health outcomes of the next generation.”

    Dr. Jai Das, Assistant Director at IGHD, emphasizes, “Childhood and adolescence provide a window of opportunity for targeting and improving behaviors and risk factors which can then lead to better health and hence productivity in adulthood.” Shockingly, the evidence on risk factors and interventions for this age group is alarmingly scarce particularly in low- and middle-income countries (LMICs), where approximately 70% of premature deaths result from health-related behaviors that originate in childhood and adolescence.

    The study found that the treatment interventions on biomarkers and adverse events for NCDs appear to be well evidenced, while interventions for mental health conditions appear to be moderately evidenced, and interventions for obesity and substance misuse appear to be moderate to very low. There is a need to prioritize action to integrate NCD actions with the child health and survival agenda, extending from early childhood to adolescence. The study also suggests that future studies should focus on evaluating the effectiveness of digital and community-based delivery platforms, especially for preventing these conditions and focusing on marginalized and at-risk populations.

    “This is the first of a series of Gap Maps conceptualized and initiated by our multi-country research group, focusing on what needs to be done to bridge the evidence divide that many LMICs face in addressing priority non-communicable diseases in children and adolescents, as only 3.8% studies were conducted in LMICs. We trust that these findings will stimulate action and implementation research in many countries confronting myriad challenges in the post-pandemic world,” says Dr Zulfiqar Bhutta, a Distinguished University Professor at IGHD-AKU.

    The findings resonate with global health goals, including the Sustainable Development Goals (SDGs) that call for a reduction in premature mortality from NCDs by one-third through prevention and management by 2030.

    Also Read: Groundbreaking Collaboration to Reduce Burden of Diabetes in Pakistan through Dream Diabetes, SMILE

  • Groundbreaking Collaboration to Reduce Burden of Diabetes in Pakistan through Dream Diabetes, SMILE

    Considering the current economic challenges and to ensure access to healthcare, Getz Pharma and M.E.D Consultants signed an MOU for the project Dream Diabetes: SMILE (Simplifying the Life of People with Type 1 Diabetes Mellitus). This initiative is designed to simplify the lives of underprivileged individuals living with Type 1 Diabetes Mellitus (T1DM) through free consultations, diagnostic tests, and Getz Pharma’s new insulin pen. This project will also provide comprehensive support, including peer assistance, educational activities, and medical support, regardless of their financial, educational, or socioeconomic backgrounds.

    “With this collaboration, Getz Pharma and M.E.D Consultants aim to significantly impact the lives of those affected by T1DM, fostering a community of support and knowledge for improved diabetes management. With the launch of our insulin pens, we aim to decrease the burden of diabetes and ensure that legacy meets convenience for people living with diabetes,” shared Dr. Jahanzeb Kamal, Senior Director of Medical Affairs – at Getz Pharma.

    “Living with T1DM is an ongoing challenge for both children and adults, requiring daily management through insulin injections and blood sugar monitoring. In low-resource countries, such as Pakistan, the complexities of managing T1DM often surpass the means of the average family”, said Dr. Syed Abbas Raza, CEO – M.E.D Consultants, during the ceremony.

    He added, “The project’s primary aim is to offer access to care and educational resources that empower individuals in their journey of managing T1DM.” Additionally, the project will extend capacity-building opportunities for healthcare professionals, enhancing their skills in T1DM management.

    Under this project, 50 children living with T1DM will be sponsored for one year. The support will ensure they can lead healthy lives despite their economic challenges.

    About Getz Pharma
    Getz Pharma is the largest pharmaceutical company in Pakistan, with a global presence in over 35 countries. It is the highest exporter, employer, investor, and taxpayer in the pharmaceutical sector of Pakistan. Getz Pharma’s manufacturing facility is approved by the Pharmaceutical Inspection Co-operation Scheme (PIC/S) member countries and the Euroasian Economic Union (EAEU). It is also South Asia’s only pharmaceutical manufacturing company to achieve the LEED (Leadership in Energy and Environmental Design) Platinum Certification from the U.S. Green Building Council (USGBC) for its Astola manufacturing facility.

    Also Read: Complications prompt diagnosis for more than three-quarters of people living with diabetes in Pakistan

  • SIEHS, CHILDLIFE sign MoU to enhance pediatric emergency, health services across Sindh

    The Sindh Integrated Emergency & Health Services (SIEHS 1122) and the ChildLife Foundation have entered a Memorandum of Understanding (MoU) for enhancing emergency and health services across Sindh.

     The partnership will enhance the capacity of the ambulance team to handle children’s emergency during transportation. It will evolve into live-teleconsultations and addition of bubble CPAP machines in the ambulances.

     Brig. (R) Tarique Quadir Lakhiar, CEO SIEHS and Dr. Ahson Rabbani, CEO of ChildLife Foundation, signed the MOU on behalf of their organizations while provincial health minister Dr. Saad Khalid Niaz was also present.

     “SIEHS plays a pivotal role in providing free ambulance services to patients across Sindh and the partnership with ChildLife will further help in saving lives of millions of children through tele-consultations of pediatric patients who require emergency care,” said Health Minister Dr. Saad Khalid Niaz.

    Under this strategic alliance, ChildLife will support SIEHS 1122 by providing live teleconsultations for pediatric patients within SIEHS 1122 ambulances while the ChildLife will seek assistance from SIEHS 1122 in efficiently transferring patients entering the ChildLife’s network. They will mutually assist in enhancing the capacity of their respective staff through collaborative efforts in capacity building.

     “This collaboration marks a crucial milestone in our mission to provide top-notch emergency and health services to the people of Sindh,” said Brig. Tarique Quadir, Chief Executive Officer SIEHS.

    Dr. Ahson Rabbani, CEO-ChildLife Foundation, said that “This collaboration is a testimony of the innovative services ChildLife team has developed and scaled. We are honored to partner with SIEHS to share our practices and experience saving lives with this virtual emergency care model throughout the province. The partnership closes the loop as it saves cost and time for poor patients who will now be transported through SIEHS ambulance services free of cost. This will allow us to save more lives across Sindh”.

    Also read  Finance Minister Chairs ECC Meeting on Power Generation Plans with K-Electric

  • ChildLife wins ‘Best Research Award’ at International Emergency Medicine Conference in UAE

    The Emirates Society of Emergency Medicine conference has evolved into a premier international platform over the years acknowledging emergency physicians with contributions towards Research in Emergency Medicine. ChildLife Foundation’s recognition reflects its outstanding contributions to emergency medicine research and its dedication to improving children’s health in Pakistan.  

    This year’s award not only acknowledges ChildLife’s commitment to advancing emergency care but also highlights its significant impact on over 200 government hospitals in Pakistan in partnership with the government. Managing 750 Emergency Room (ER) beds in pediatric Emergency Departments (EDs) and offering 24/7 telemedicine support in secondary care hospitals, ChildLife’s impact to date can be gauged by the fact that 7.5 million children have been treated free of cost in EDs with 4 times increase in the survival rate of critically ill children. 

    Read more Meezan Bank Partners with Befiler to Provide Tax Facilitation Services for Freelancers

    The ESEM Awards were launched at the celebration of 10 years’ journey of ESEM to recognize the excellence of physicians and their outstanding contributions towards Research in the field of Emergency Medicine. ChildLife Foundation, a consistent contributor, has been awarded for the highest research and abstract submissions since the conference’s inception in 2014, held in Abu Dhabi from 6-9 December 2023.  

    “We are honored to receive the Best Research Award at ESEM Conference 2023, recognizing our unwavering commitment to contribute towards advancing emergency care for children. This achievement is a testament to the hard work and commitment to make Pakistan a child-safe country”, said Dr. Ahson Rabbani, CEO of ChildLife Foundation.